data_1k45_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1k45 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.8 ttt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.463 -0.569 . . . . 2.2799999999999998 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.7 mt -66.79 -171.39 0.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 2.3799999999999999 109.468 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.529 ' CG2' ' HB1' ' A' ' 165' ' ' ALA . 3.0 p -178.19 173.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 1.21 109.484 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.551 ' CB ' HG12 ' A' ' 78' ' ' VAL . . . -71.18 -60.71 2.09 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 1.1200000000000001 109.403 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.515 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 54.0 t-20 -75.78 131.68 39.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 1.8 109.394 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.516 ' O ' ' CA ' ' A' ' 27' ' ' GLY . 4.0 mt -110.09 125.93 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 1.6799999999999999 109.558 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.534 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.1 OUTLIER 57.75 30.1 18.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 1.75 109.679 179.874 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.419 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -67.2 -8.98 53.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.395 -1.482 . . . . 0.77000000000000002 109.395 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.478 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -123.02 16.33 8.2 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.499 -1.44 . . . . 1.3700000000000001 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.571 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 18.7 m-85 63.66 17.3 10.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -1.157 . . . . 3.3900000000000001 109.484 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.518 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 10.2 mt-10 -60.61 -49.83 75.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.24 -0.913 . . . . 2.1099999999999999 109.528 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -85.15 14.71 4.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 1.79 109.527 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.468 ' O ' ' HD3' ' A' ' 55' ' ' LYS . 1.9 m -107.34 128.38 26.09 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.211 -0.931 . . . . 1.3500000000000001 109.27 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.1 Cg_endo -76.97 130.79 11.58 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.491 2.128 . . . . 0.68999999999999995 110.642 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -43.45 169.21 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.725 -0.609 . . . . 1.1299999999999999 109.624 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.25 132.22 3.41 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.992 -1.643 . . . . 0.41999999999999998 108.992 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.525 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.75 142.44 12.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.232 -1.158 . . . . 1.1000000000000001 109.153 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.2 t -84.84 146.88 6.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.434 -0.791 . . . . 1.1599999999999999 110.311 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.4 p -110.24 -25.49 10.12 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.46 -0.941 . . . . 1.79 108.46 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.519 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.5 m-20 -141.86 94.93 2.73 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.599 -0.889 . . . . 1.6000000000000001 108.599 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.625 ' CB ' ' HB2' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -50.17 -34.36 22.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.898 . . . . 1.95 109.909 -179.177 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.535 ' N ' HD11 ' A' ' 21' ' ' LEU . . . -64.3 -39.72 94.49 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.194 -0.941 . . . . 1.3799999999999999 109.365 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.519 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 5.0 pt-20 -118.74 36.91 4.25 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.295 -0.878 . . . . 1.8600000000000001 109.483 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.21 -76.69 1.29 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.403 -1.479 . . . . 1.1799999999999999 109.403 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.509 ' HB ' ' O ' ' A' ' 28' ' ' TRP . 58.6 t -95.34 128.14 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -1.149 . . . . 1.79 109.119 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -68.04 -36.38 79.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.284 -0.885 . . . . 1.8700000000000001 109.86 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.534 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -84.49 -13.93 72.11 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.071 -1.212 . . . . 1.1599999999999999 110.071 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TRP . . . . . 0.604 ' CE3' ' HB2' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.02 126.37 21.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.039 -1.271 . . . . 0.48999999999999999 110.141 -179.778 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.455 ' OD2' ' O ' ' A' ' 22' ' ' ALA . 0.6 OUTLIER -118.86 144.09 46.58 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.103 -1.073 . . . . 1.4399999999999999 108.103 178.826 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.656 ' CD1' ' CD1' ' A' ' 42' ' ' PHE . 1.0 OUTLIER -118.31 161.76 19.4 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.753 -1.217 . . . . 1.3700000000000001 109.739 -179.41 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -154.33 123.3 6.33 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.435 -0.791 . . . . 1.8500000000000001 109.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.541 HG13 ' CG2' ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.82 137.68 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 1.1200000000000001 109.674 179.739 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.61 179.59 23.56 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.403 -1.479 . . . . 0.48999999999999999 109.403 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.3 m -58.84 -14.88 10.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.176 -1.191 . . . . 1.8200000000000001 109.392 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.479 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.9 p -63.69 -36.57 84.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.228 -0.92 . . . . 1.3 109.597 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.541 ' CG2' HG13 ' A' ' 32' ' ' VAL . 2.1 t -66.32 93.11 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.158 -0.964 . . . . 1.26 109.726 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 92.8 m -74.73 -27.22 60.27 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.428 -0.795 . . . . 1.54 108.926 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.539 ' O ' HG11 ' A' ' 36' ' ' VAL . 1.2 t-20 -111.31 141.4 24.34 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 109.212 -0.662 . . . . 2.3700000000000001 109.212 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.452 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 35.2 Cg_endo -76.95 111.85 3.31 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.466 2.111 . . . . 1.6699999999999999 110.679 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.521 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -78.02 166.91 24.3 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.573 2.182 . . . . 0.92000000000000004 109.859 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.589 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 41.9 t -109.57 122.64 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.092 -1.005 . . . . 1.03 110.413 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.656 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 40.2 m-85 -110.96 112.81 24.91 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.107 -1.072 . . . . 2.3300000000000001 108.107 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.8 tm-20 -151.52 145.77 25.41 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.125 -0.985 . . . . 1.6100000000000001 109.932 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 56' ' ' VAL . 40.3 t -90.95 148.57 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.368 -0.832 . . . . 1.1499999999999999 109.323 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.59 ' HG ' ' N ' ' A' ' 46' ' ' GLU . 0.4 OUTLIER -137.12 147.7 46.18 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.179 -0.951 . . . . 2.5699999999999998 108.884 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.59 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 11.7 mt-10 -112.0 111.98 23.28 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.572 -0.705 . . . . 1.8899999999999999 109.478 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.517 ' CG2' HD21 ' A' ' 45' ' ' LEU . 2.0 p -135.16 144.56 47.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.395 -0.815 . . . . 1.8600000000000001 109.486 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.9 m -68.44 -18.06 64.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 2.2999999999999998 109.506 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 50' ' ' ALA . 4.1 m-20 -76.56 -10.74 59.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.902 . . . . 1.78 109.514 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 49' ' ' ASP . . . -44.04 147.83 0.87 Allowed Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 1.25 109.436 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.584 ' HG3' ' CE3' ' A' ' 125' ' ' TRP . 35.6 Cg_endo -78.21 -41.11 0.3 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.771 2.314 . . . . 0.73999999999999999 110.372 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -126.31 108.19 11.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 2.2000000000000002 109.364 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.43 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 81.89 -121.56 5.46 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.437 -1.465 . . . . 0.72999999999999998 109.437 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 5.1 m120 -159.12 23.33 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 2.7799999999999998 109.513 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.523 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 43.5 mttt -134.15 139.55 45.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 1.8300000000000001 109.61 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 55' ' ' LYS . 4.1 m -148.18 174.5 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 1.1299999999999999 109.462 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LEU . . . . . 0.571 ' HB2' ' CE1' ' A' ' 10' ' ' PHE . 0.1 OUTLIER -104.8 99.23 8.88 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.906 . . . . 1.1000000000000001 108.983 179.544 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.671 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.71 114.09 20.14 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.288 -0.883 . . . . 1.03 108.762 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 27.5 t -110.58 144.97 17.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.217 -0.927 . . . . 1.0800000000000001 109.042 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' THR . . . . . 0.545 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 3.2 m -108.04 89.13 2.9 Favored 'General case' 0 C--N 1.283 -2.29 0 N-CA-C 108.966 -0.753 . . . . 1.1100000000000001 108.966 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' VAL . . . . . 0.531 ' CG2' ' CD1' ' A' ' 157' ' ' ILE . 39.0 t -83.43 129.39 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.32 -0.862 . . . . 1.02 109.228 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -160.08 61.58 0.35 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.59999999999999998 109.776 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 150.14 94.92 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.785 -1.326 . . . . 0.33000000000000002 109.785 179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.541 HG13 ' CA ' ' A' ' 149' ' ' TYR . 2.3 m -79.95 -171.27 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.187 -1.184 . . . . 1.1499999999999999 109.455 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -132.66 -162.97 10.46 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.588 -1.405 . . . . 0.44 109.588 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -85.14 4.12 35.88 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.267 -1.137 . . . . 1.95 109.511 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.585 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 89.7 m-20 -127.94 149.34 70.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 1.76 109.447 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.557 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.2 Cg_endo -78.61 13.35 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 C-N-CA 122.643 2.229 . . . . 0.59999999999999998 110.735 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.585 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -135.34 56.93 1.82 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.073 -1.017 . . . . 0.77000000000000002 109.888 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.471 ' OD1' ' O ' ' A' ' 67' ' ' ASN . 0.4 OUTLIER -79.29 -67.53 0.75 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -0.91 . . . . 1.4099999999999999 109.077 179.607 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.521 ' CG1' ' HG3' ' A' ' 40' ' ' PRO . 3.2 mp -98.52 128.67 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.328 -0.858 . . . . 1.3100000000000001 108.926 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -134.46 122.05 21.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 2.0699999999999998 109.893 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . 0.734 ' O ' HG12 ' A' ' 145' ' ' ILE . . . -114.69 108.31 16.63 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.285 -0.884 . . . . 1.1799999999999999 108.785 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.489 ' OG1' ' HA ' ' A' ' 144' ' ' PRO . 91.4 m -97.94 163.08 12.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.433 -0.792 . . . . 1.1000000000000001 109.782 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 76' ' ' PHE . . . -118.32 139.67 50.99 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.109 -0.994 . . . . 1.1200000000000001 109.099 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.696 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.2 p90 175.84 169.32 0.37 Allowed Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.503 -0.748 . . . . 2.3399999999999999 109.066 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.696 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.51 165.07 78.09 Favored 'Cis proline' 0 C--N 1.309 -1.529 0 C-N-CA 123.549 -1.438 . . . . 0.5 110.654 -0.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.551 HG12 ' CB ' ' A' ' 4' ' ' ALA . 90.0 t -124.61 156.18 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.333 -0.855 . . . . 1.23 108.995 179.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASN . . . . . 0.492 ' O ' ' HB1' ' A' ' 4' ' ' ALA . 76.2 m-20 -123.35 122.48 38.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 1.6200000000000001 109.917 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.575 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.7 m -126.89 -173.96 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 1.1599999999999999 109.44 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.552 ' O ' ' CG2' ' A' ' 134' ' ' VAL . 3.5 mtt180 -136.09 146.61 57.23 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.297 -0.877 . . . . 3.3599999999999999 109.293 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.78 103.73 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.589 2.193 . . . . 0.5 110.467 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 115.91 -35.78 4.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.45000000000000001 109.601 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 t -82.3 149.49 4.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.267 -1.137 . . . . 1.26 109.667 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 132' ' ' PHE . 24.1 m -97.19 134.95 39.83 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 109.37 -0.604 . . . . 1.6799999999999999 109.37 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . 0.575 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 6.2 m-85 -108.84 171.58 7.35 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 2.1200000000000001 109.603 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . 0.483 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.2 m -118.18 154.22 32.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 1.1000000000000001 109.477 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.693 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.3 t80 -130.97 117.39 19.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 5.1799999999999997 109.324 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.6 m -135.19 143.59 46.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.933 . . . . 1.0700000000000001 109.337 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.496 ' C ' ' CD1' ' A' ' 91' ' ' TRP . 17.4 tt -150.17 163.07 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.865 -1.147 . . . . 1.1499999999999999 109.473 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.579 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 20.5 m95 -131.68 126.58 34.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.989 -1.069 . . . . 0.34999999999999998 109.235 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -114.79 148.26 38.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.268 -0.895 . . . . 0.95999999999999996 109.568 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.566 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 19.2 ttp85 -162.64 121.49 2.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 2.3700000000000001 109.222 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -109.13 152.44 25.09 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.907 . . . . 1.04 109.825 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -52.09 -36.96 52.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.356 -0.84 . . . . 2.0499999999999998 109.408 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.469 ' HB2' ' OD1' ' A' ' 155' ' ' ASN . 2.9 mt-30 -121.05 143.0 49.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.263 -0.898 . . . . 2.6699999999999999 109.41 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.577 ' N ' ' CG2' ' A' ' 123' ' ' THR . 30.4 p30 -68.89 164.25 22.53 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.246 -0.909 . . . . 1.9199999999999999 109.494 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 88.48 43.9 5.4 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.611 -1.395 . . . . 0.38 109.611 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.509 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -122.96 142.54 50.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.192 -1.181 . . . . 1.03 108.917 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.517 HG12 ' N ' ' A' ' 101' ' ' VAL . 46.3 t -114.5 145.83 19.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 121.178 -0.952 . . . . 1.02 110.725 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.671 ' CG1' ' CZ ' ' A' ' 147' ' ' PHE . 60.5 t -146.93 163.59 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.545 -0.722 . . . . 1.04 109.368 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.676 ' HB2' ' HB2' ' A' ' 146' ' ' HIS . 49.4 m -127.29 132.45 50.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.106 -0.997 . . . . 1.8 109.702 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . 0.643 ' CD1' ' N ' ' A' ' 103' ' ' PHE . 0.3 OUTLIER -128.28 104.27 7.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.173 -0.954 . . . . 2.3199999999999998 109.636 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.575 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.2 p -122.72 168.9 11.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.132 -0.98 . . . . 1.05 110.512 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.744 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.58 152.92 32.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-O 121.271 0.558 . . . . 1.1100000000000001 109.762 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 179.19 148.26 7.64 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.529 -1.428 . . . . 0.77000000000000002 109.529 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.462 ' HB3' ' OH ' ' A' ' 113' ' ' TYR . 0.0 OUTLIER -92.21 -170.65 2.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.177 -1.19 . . . . 2.1400000000000001 109.635 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -61.43 -26.5 67.91 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.27 -0.894 . . . . 1.1899999999999999 110.64 -179.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.483 ' O ' ' HB2' ' A' ' 110' ' ' PHE . 0.3 OUTLIER -79.42 9.31 4.92 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.072 -1.017 . . . . 1.72 110.04 -179.475 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PHE . . . . . 0.52 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.6 m-30 71.75 1.89 4.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 2.4700000000000002 109.809 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLN . . . . . 0.473 ' O ' ' HA2' ' A' ' 106' ' ' GLY . 12.0 mm100 -69.89 104.51 2.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.161 -0.962 . . . . 2.48 109.135 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.507 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 6.3 tt0 -89.28 144.52 26.03 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.299 -0.875 . . . . 1.6200000000000001 109.825 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.576 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.1 m-85 -107.97 -69.87 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.419 -0.801 . . . . 2.3799999999999999 109.005 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.534 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -86.42 162.8 35.13 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.232 -1.547 . . . . 0.63 109.232 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.533 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -157.59 116.16 3.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.07 -1.253 . . . . 3.5699999999999998 110.103 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.582 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -147.46 81.39 1.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 1.3300000000000001 108.893 179.391 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . 0.562 ' CB ' ' HB3' ' A' ' 102' ' ' SER . 34.5 p-80 -126.38 166.07 17.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 4.3700000000000001 110.083 -179.395 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 6.9 tt0 77.36 57.12 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.38 -0.825 . . . . 2.5099999999999998 109.351 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -137.81 144.06 41.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.303 -0.873 . . . . 2.29 109.731 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLN . . . . . 0.464 ' O ' HD13 ' A' ' 121' ' ' ILE . 38.6 mt-30 -75.6 156.77 34.6 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.516 -0.74 . . . . 2.5499999999999998 109.062 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.464 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.3 mm -132.91 138.44 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.189 -0.945 . . . . 1.1100000000000001 110.012 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -81.21 -179.34 7.32 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.516 -0.74 . . . . 1.0700000000000001 110.061 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.577 ' CG2' ' N ' ' A' ' 97' ' ' ASP . 81.9 p -78.64 2.64 18.74 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.931 -0.708 . . . . 1.0800000000000001 109.283 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.509 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 35.9 mt-10 -112.6 -169.06 1.4 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.224 -0.922 . . . . 2.0099999999999998 109.375 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' TRP . . . . . 0.584 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 88.8 m95 -93.6 126.96 39.05 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.245 -0.909 . . . . 0.51000000000000001 109.575 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.466 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.3 mt-30 -106.97 121.21 45.57 Favored Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.192 -0.942 . . . . 1.75 109.033 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.57 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.4 Cg_endo -79.33 103.72 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.515 2.143 . . . . 0.35999999999999999 110.864 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.45 134.68 54.82 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.276 -1.009 . . . . 2.21 108.276 179.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.538 ' OG1' ' O ' ' A' ' 88' ' ' TYR . 15.2 t -151.65 176.96 10.85 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 122.485 1.136 . . . . 1.1299999999999999 110.866 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.693 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 34.4 p90 -170.43 -174.71 1.73 Allowed 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.064 -0.971 . . . . 2.1800000000000002 109.281 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 45.5 mt-10 -129.81 150.24 51.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 1.5 109.869 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.576 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -164.91 168.14 17.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.849 . . . . 5.2999999999999998 109.209 179.818 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.482 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -139.41 146.68 40.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 1.22 109.634 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.552 ' CG2' ' O ' ' A' ' 81' ' ' ARG . 13.5 t -38.63 110.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.426 -0.796 . . . . 1.1299999999999999 109.352 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.31 -54.09 45.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.255 -0.903 . . . . 1.3999999999999999 109.195 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.461 ' O ' ' CG ' ' A' ' 137' ' ' GLN . 1.1 m-20 -103.12 -95.3 0.31 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.369 -0.832 . . . . 1.9399999999999999 109.194 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.461 ' CG ' ' O ' ' A' ' 136' ' ' ASP . 51.4 mt-30 -157.14 52.96 0.49 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.409 -0.807 . . . . 2.7000000000000002 109.122 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . 0.465 ' O ' HG23 ' A' ' 80' ' ' VAL . 25.8 mm-40 -93.71 113.64 25.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 1.51 109.729 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.67 -8.69 59.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 1.02 108.768 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.521 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -138.35 134.88 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.811 -0.811 . . . . 1.21 108.811 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.48 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -141.26 172.01 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.14 -0.975 . . . . 1.1200000000000001 110.006 -179.781 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ARG . . . . . 0.545 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.6 ptm180 -148.86 133.51 17.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.541 -0.725 . . . . 2.2599999999999998 109.35 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ALA . . . . . 0.744 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.44 107.95 33.22 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.344 -0.847 . . . . 1.04 109.613 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PRO . . . . . 0.575 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.3 Cg_endo -75.84 110.81 3.15 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.269 1.979 . . . . 0.39000000000000001 110.396 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ILE . . . . . 0.734 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.8 mm -91.82 129.74 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.177 -1.046 . . . . 1.8 108.177 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' HIS . . . . . 0.676 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 9.8 m80 -89.44 156.96 18.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.913 -1.117 . . . . 1.1000000000000001 110.691 -178.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.671 ' CZ ' ' CG1' ' A' ' 101' ' ' VAL . 61.2 m-85 -161.12 156.63 24.73 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.323 -0.991 . . . . 2.5499999999999998 108.323 179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.444 ' C ' HG13 ' A' ' 64' ' ' VAL . . . 109.09 53.25 0.62 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.394 -1.483 . . . . 0.62 109.394 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 0.557 ' CE1' ' O ' ' A' ' 68' ' ' PRO . 66.3 m-85 -127.6 155.8 43.29 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.31 -1.112 . . . . 2.1899999999999999 109.346 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.7 -29.61 70.6 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.169 -0.678 . . . . 1.0600000000000001 109.169 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.491 ' HB3' ' HB ' ' A' ' 100' ' ' VAL . . . -71.35 -11.79 61.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.395 -0.816 . . . . 1.1399999999999999 109.125 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.532 ' ND2' ' CD1' ' A' ' 157' ' ' ILE . 4.3 t-20 -118.33 9.6 12.52 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.947 -1.131 . . . . 2.0899999999999999 107.947 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.482 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 2.1 t -81.79 161.34 3.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.435 0.636 . . . . 1.0800000000000001 109.963 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.482 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.94 34.91 62.29 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.787 -1.325 . . . . 0.25 109.787 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.469 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 6.6 m-20 -160.46 143.78 13.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.132 -1.217 . . . . 0.66000000000000003 109.975 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' THR . . . . . 0.614 ' CG2' ' CE1' ' A' ' 158' ' ' TYR . 95.4 m -89.64 125.5 35.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.465 -0.939 . . . . 1.03 108.465 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.532 ' CD1' ' ND2' ' A' ' 152' ' ' ASN . 1.0 OUTLIER -103.6 118.56 50.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.938 -1.101 . . . . 1.1000000000000001 110.185 -179.095 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.671 ' CE2' ' CB ' ' A' ' 58' ' ' ALA . 2.3 m-85 -100.59 127.83 46.85 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 107.907 -1.146 . . . . 2.0800000000000001 107.907 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.638 ' CD1' ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.39 140.02 45.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 120.919 -1.113 . . . . 1.0900000000000001 110.255 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 161' ' ' GLY . 9.8 t0 -173.71 136.64 0.57 Allowed 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.292 -0.88 . . . . 1.1299999999999999 108.986 179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.31 -8.18 8.47 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.544 -1.312 . . . . 0.23000000000000001 110.036 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.603 HD11 ' CE2' ' A' ' 88' ' ' TYR . 0.4 OUTLIER -60.4 100.13 0.09 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.954 -1.321 . . . . 1.4199999999999999 108.747 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . 0.457 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -133.6 145.61 50.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 1.0800000000000001 109.763 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.527 ' CD1' HG11 ' A' ' 78' ' ' VAL . 3.5 mt -125.3 108.99 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 1.5600000000000001 109.307 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . 0.529 ' HB1' ' CG2' ' A' ' 3' ' ' VAL . . . -156.39 151.37 26.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.177 -0.952 . . . . 1.1200000000000001 109.63 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 24.9 p -87.11 171.56 10.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 1.8200000000000001 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.466 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 0.3 OUTLIER -105.94 161.09 23.91 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 3.5800000000000001 109.454 179.986 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.2 Cg_endo . . . . . 0 C--N 1.307 -1.655 0 C-N-CA 122.733 2.289 . . . . 4.8499999999999996 110.409 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.8 ttt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.463 -0.569 . . . . 1.79 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.7 mt -66.79 -171.39 0.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 1.8899999999999999 109.468 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.958 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 3.0 p -178.19 173.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.60999999999999999 109.484 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.764 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -71.18 -60.71 2.09 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.53000000000000003 109.403 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.637 ' HB2' HD12 ' A' ' 164' ' ' ILE . 54.0 t-20 -75.78 131.68 39.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 1.8 109.394 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.516 ' O ' ' CA ' ' A' ' 27' ' ' GLY . 4.0 mt -110.09 125.93 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 1.1399999999999999 109.558 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.659 ' ND2' ' CB ' ' A' ' 12' ' ' SER . 0.7 OUTLIER 57.75 30.1 18.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 1.75 109.679 179.874 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -67.2 -8.98 53.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.395 -1.482 . . . . 0.70999999999999996 109.395 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.498 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -123.02 16.33 8.2 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.499 -1.44 . . . . 1.0600000000000001 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.591 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 18.7 m-85 63.66 17.3 10.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -1.157 . . . . 2.6600000000000001 109.484 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.518 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 10.2 mt-10 -60.61 -49.83 75.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.24 -0.913 . . . . 2.1099999999999999 109.528 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.659 ' CB ' ' ND2' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -85.15 14.71 4.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 1.4399999999999999 109.527 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.658 HG21 HG22 ' A' ' 25' ' ' VAL . 1.9 m -107.34 128.38 26.09 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.211 -0.931 . . . . 0.82999999999999996 109.27 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.1 Cg_endo -76.97 130.79 11.58 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.491 2.128 . . . . 0.59999999999999998 110.642 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -43.45 169.21 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.725 -0.609 . . . . 0.42999999999999999 109.624 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.25 132.22 3.41 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.992 -1.643 . . . . 0.38 108.992 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.75 142.44 12.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.232 -1.158 . . . . 0.42999999999999999 109.153 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.2 t -84.84 146.88 6.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.434 -0.791 . . . . 0.40999999999999998 110.311 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.4 p -110.24 -25.49 10.12 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.46 -0.941 . . . . 1.3300000000000001 108.46 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.545 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.5 m-20 -141.86 94.93 2.73 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.599 -0.889 . . . . 1.6000000000000001 108.599 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.999 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -50.17 -34.36 22.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.898 . . . . 1.26 109.909 -179.177 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.921 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -64.3 -39.72 94.49 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.194 -0.941 . . . . 0.97999999999999998 109.365 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.545 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 5.0 pt-20 -118.74 36.91 4.25 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.295 -0.878 . . . . 1.8600000000000001 109.483 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.21 -76.69 1.29 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.403 -1.479 . . . . 1.1799999999999999 109.403 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.658 HG22 HG21 ' A' ' 13' ' ' THR . 58.6 t -95.34 128.14 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -1.149 . . . . 1.26 109.119 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -68.04 -36.38 79.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.284 -0.885 . . . . 1.8700000000000001 109.86 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -84.49 -13.93 72.11 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.071 -1.212 . . . . 0.47999999999999998 110.071 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TRP . . . . . 0.619 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.02 126.37 21.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.039 -1.271 . . . . 0.41999999999999998 110.141 -179.778 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.762 ' C ' HD23 ' A' ' 30' ' ' LEU . 0.6 OUTLIER -118.86 144.09 46.58 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.103 -1.073 . . . . 1.4399999999999999 108.103 178.826 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.999 ' O ' HD13 ' A' ' 21' ' ' LEU . 1.0 OUTLIER -118.31 161.76 19.4 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.753 -1.217 . . . . 0.62 109.739 -179.41 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -154.33 123.3 6.33 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.435 -0.791 . . . . 1.1499999999999999 109.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.899 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.82 137.68 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.40000000000000002 109.674 179.739 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.61 179.59 23.56 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.403 -1.479 . . . . 0.40999999999999998 109.403 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.3 m -58.84 -14.88 10.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.176 -1.191 . . . . 1.3500000000000001 109.392 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.9 p -63.69 -36.57 84.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.228 -0.92 . . . . 0.91000000000000003 109.597 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.899 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -66.32 93.11 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.158 -0.964 . . . . 0.53000000000000003 109.726 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 92.8 m -74.73 -27.22 60.27 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.428 -0.795 . . . . 1.04 108.926 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -111.31 141.4 24.34 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 109.212 -0.662 . . . . 1.9199999999999999 109.212 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.477 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 35.2 Cg_endo -76.95 111.85 3.31 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.466 2.111 . . . . 1.3600000000000001 110.679 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.537 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -78.02 166.91 24.3 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.573 2.182 . . . . 0.76000000000000001 109.859 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.601 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 41.9 t -109.57 122.64 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.092 -1.005 . . . . 0.25 110.413 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.745 ' CD1' HD13 ' A' ' 30' ' ' LEU . 40.2 m-85 -110.96 112.81 24.91 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.107 -1.072 . . . . 1.45 108.107 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.8 tm-20 -151.52 145.77 25.41 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.125 -0.985 . . . . 1.6100000000000001 109.932 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.95 148.57 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.368 -0.832 . . . . 0.38 109.323 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 1.053 HD21 HG23 ' A' ' 47' ' ' THR . 0.4 OUTLIER -137.12 147.7 46.18 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.179 -0.951 . . . . 1.97 108.884 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.598 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 11.7 mt-10 -112.0 111.98 23.28 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.572 -0.705 . . . . 1.8600000000000001 109.478 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . 1.053 HG23 HD21 ' A' ' 45' ' ' LEU . 2.0 p -135.16 144.56 47.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.395 -0.815 . . . . 1.1799999999999999 109.486 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.9 m -68.44 -18.06 64.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 1.8400000000000001 109.506 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 50' ' ' ALA . 4.1 m-20 -76.56 -10.74 59.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.902 . . . . 1.78 109.514 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.464 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.04 147.83 0.87 Allowed Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.56999999999999995 109.436 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.6 Cg_endo -78.21 -41.11 0.3 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.771 2.314 . . . . 0.73999999999999999 110.372 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -126.31 108.19 11.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 2.2000000000000002 109.364 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.43 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 81.89 -121.56 5.46 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.437 -1.465 . . . . 0.60999999999999999 109.437 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 5.1 m120 -159.12 23.33 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 2.2599999999999998 109.513 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.523 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 43.5 mttt -134.15 139.55 45.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 1.28 109.61 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.665 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -148.18 174.5 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.44 109.462 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LEU . . . . . 0.634 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.1 OUTLIER -104.8 99.23 8.88 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.906 . . . . 0.25 108.983 179.544 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.671 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.71 114.09 20.14 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.288 -0.883 . . . . 0.17999999999999999 108.762 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.805 ' O ' HG23 ' A' ' 156' ' ' THR . 27.5 t -110.58 144.97 17.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.217 -0.927 . . . . 0.17000000000000001 109.042 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' THR . . . . . 0.555 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 3.2 m -108.04 89.13 2.9 Favored 'General case' 0 C--N 1.283 -2.29 0 N-CA-C 108.966 -0.753 . . . . 0.27000000000000002 108.966 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' VAL . . . . . 0.555 HG21 ' CD1' ' A' ' 157' ' ' ILE . 39.0 t -83.43 129.39 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.32 -0.862 . . . . 0.28999999999999998 109.228 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -160.08 61.58 0.35 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.53000000000000003 109.776 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.41 ' HA3' ' HB2' ' A' ' 38' ' ' ASN . . . 150.14 94.92 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.785 -1.326 . . . . 0.29999999999999999 109.785 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.658 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.95 -171.27 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.187 -1.184 . . . . 0.34000000000000002 109.455 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -132.66 -162.97 10.46 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.588 -1.405 . . . . 0.44 109.588 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -85.14 4.12 35.88 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.267 -1.137 . . . . 1.6699999999999999 109.511 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.591 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 89.7 m-20 -127.94 149.34 70.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 1.51 109.447 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.557 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.2 Cg_endo -78.61 13.35 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 C-N-CA 122.643 2.229 . . . . 0.55000000000000004 110.735 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.591 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -135.34 56.93 1.82 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.073 -1.017 . . . . 0.68999999999999995 109.888 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.56 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -79.29 -67.53 0.75 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -0.91 . . . . 1.4099999999999999 109.077 179.607 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.73 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 3.2 mp -98.52 128.67 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.328 -0.858 . . . . 0.62 108.926 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 145' ' ' ILE . 43.0 tt0 -134.46 122.05 21.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 2.0699999999999998 109.893 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . 0.741 ' O ' HG12 ' A' ' 145' ' ' ILE . . . -114.69 108.31 16.63 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.285 -0.884 . . . . 0.39000000000000001 108.785 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.518 HG22 ' N ' ' A' ' 75' ' ' ALA . 91.4 m -97.94 163.08 12.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.433 -0.792 . . . . 0.39000000000000001 109.782 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.518 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.32 139.67 50.99 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.109 -0.994 . . . . 0.34000000000000002 109.099 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.699 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.2 p90 175.84 169.32 0.37 Allowed Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.503 -0.748 . . . . 1.4399999999999999 109.066 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.699 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.51 165.07 78.09 Favored 'Cis proline' 0 C--N 1.309 -1.529 0 C-N-CA 123.549 -1.438 . . . . 0.46999999999999997 110.654 -0.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 164' ' ' ILE . 90.0 t -124.61 156.18 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.333 -0.855 . . . . 0.35999999999999999 108.995 179.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASN . . . . . 0.46 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 76.2 m-20 -123.35 122.48 38.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 1.3400000000000001 109.917 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.58 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.7 m -126.89 -173.96 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 0.33000000000000002 109.44 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.638 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.5 mtt180 -136.09 146.61 57.23 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.297 -0.877 . . . . 2.8500000000000001 109.293 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.78 103.73 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.589 2.193 . . . . 0.46999999999999997 110.467 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 115.91 -35.78 4.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.45000000000000001 109.601 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 t -82.3 149.49 4.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.267 -1.137 . . . . 0.53000000000000003 109.667 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 132' ' ' PHE . 24.1 m -97.19 134.95 39.83 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 109.37 -0.604 . . . . 1.21 109.37 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' TYR . . . . . 0.58 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 6.2 m-85 -108.84 171.58 7.35 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 1.25 109.603 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.2 m -118.18 154.22 32.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.56000000000000005 109.477 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.693 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.3 t80 -130.97 117.39 19.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 4.9500000000000002 109.324 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.6 m -135.19 143.59 46.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.933 . . . . 0.28000000000000003 109.337 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.725 HD13 ' CD2' ' A' ' 103' ' ' PHE . 17.4 tt -150.17 163.07 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.865 -1.147 . . . . 0.40999999999999998 109.473 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.604 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 20.5 m95 -131.68 126.58 34.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.989 -1.069 . . . . 0.29999999999999999 109.235 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -114.79 148.26 38.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.268 -0.895 . . . . 0.29999999999999999 109.568 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.563 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 19.2 ttp85 -162.64 121.49 2.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 1.8500000000000001 109.222 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -109.13 152.44 25.09 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.907 . . . . 0.20999999999999999 109.825 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.413 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.2 OUTLIER -52.09 -36.96 52.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.356 -0.84 . . . . 2.0499999999999998 109.408 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.542 ' C ' HG22 ' A' ' 123' ' ' THR . 12.1 mt-30 -121.05 143.0 49.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.263 -0.898 . . . . 2.23 109.41 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.634 ' N ' HG22 ' A' ' 123' ' ' THR . 30.4 p30 -68.89 164.25 22.53 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.246 -0.909 . . . . 1.9199999999999999 109.494 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 88.48 43.9 5.4 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.611 -1.395 . . . . 0.34000000000000002 109.611 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.931 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -122.96 142.54 50.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.192 -1.181 . . . . 0.26000000000000001 108.917 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 46.3 t -114.5 145.83 19.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 121.178 -0.952 . . . . 0.28000000000000003 110.725 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.701 HG13 ' CE1' ' A' ' 147' ' ' PHE . 60.5 t -146.93 163.59 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.545 -0.722 . . . . 0.31 109.368 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.661 ' HB2' ' HB2' ' A' ' 146' ' ' HIS . 49.4 m -127.29 132.45 50.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.106 -0.997 . . . . 1.3300000000000001 109.702 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.725 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -128.28 104.27 7.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.173 -0.954 . . . . 1.3899999999999999 109.636 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.584 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.2 p -122.72 168.9 11.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.132 -0.98 . . . . 0.35999999999999999 110.512 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.58 152.92 32.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-O 121.271 0.558 . . . . 0.46000000000000002 109.762 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 179.19 148.26 7.64 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.529 -1.428 . . . . 0.62 109.529 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.473 ' HB3' HG22 ' A' ' 141' ' ' ILE . 0.0 OUTLIER -92.21 -170.65 2.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.177 -1.19 . . . . 2.1400000000000001 109.635 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -61.43 -26.5 67.91 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.27 -0.894 . . . . 1.1299999999999999 110.64 -179.068 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.49 ' HB3' ' HG2' ' A' ' 111' ' ' GLN . 0.3 OUTLIER -79.42 9.31 4.92 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.072 -1.017 . . . . 1.55 110.04 -179.475 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PHE . . . . . 0.52 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.6 m-30 71.75 1.89 4.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 1.6799999999999999 109.809 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLN . . . . . 0.49 ' O ' ' HA2' ' A' ' 106' ' ' GLY . 12.0 mm100 -69.89 104.51 2.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.161 -0.962 . . . . 2.2400000000000002 109.135 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 6.3 tt0 -89.28 144.52 26.03 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.299 -0.875 . . . . 1.6200000000000001 109.825 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.576 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.1 m-85 -107.97 -69.87 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.419 -0.801 . . . . 1.5 109.005 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.546 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -86.42 162.8 35.13 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.232 -1.547 . . . . 0.5 109.232 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.533 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -157.59 116.16 3.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.07 -1.253 . . . . 2.9700000000000002 110.103 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -147.46 81.39 1.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.56000000000000005 108.893 179.391 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 34.5 p-80 -126.38 166.07 17.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 3.6400000000000001 110.083 -179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 6.9 tt0 77.36 57.12 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.38 -0.825 . . . . 2.5099999999999998 109.351 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -137.81 144.06 41.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.303 -0.873 . . . . 2.29 109.731 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLN . . . . . 0.633 ' O ' HD13 ' A' ' 121' ' ' ILE . 38.6 mt-30 -75.6 156.77 34.6 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.516 -0.74 . . . . 2.0299999999999998 109.062 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.633 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.3 mm -132.91 138.44 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.189 -0.945 . . . . 0.38 110.012 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -81.21 -179.34 7.32 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.516 -0.74 . . . . 0.27000000000000002 110.061 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.634 HG22 ' N ' ' A' ' 97' ' ' ASP . 81.9 p -78.64 2.64 18.74 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.931 -0.708 . . . . 0.40000000000000002 109.283 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 35.9 mt-10 -112.6 -169.06 1.4 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.224 -0.922 . . . . 2.0099999999999998 109.375 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' TRP . . . . . 0.58 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 88.8 m95 -93.6 126.96 39.05 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.245 -0.909 . . . . 0.44 109.575 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.3 mt-30 -106.97 121.21 45.57 Favored Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.192 -0.942 . . . . 1.6499999999999999 109.033 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.586 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.4 Cg_endo -79.33 103.72 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.515 2.143 . . . . 0.32000000000000001 110.864 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.45 134.68 54.82 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.276 -1.009 . . . . 1.28 108.276 179.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 15.2 t -151.65 176.96 10.85 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 122.485 1.136 . . . . 0.40000000000000002 110.866 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.693 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 34.4 p90 -170.43 -174.71 1.73 Allowed 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.064 -0.971 . . . . 1.47 109.281 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 45.5 mt-10 -129.81 150.24 51.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 1.5 109.869 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.576 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -164.91 168.14 17.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.849 . . . . 4.2800000000000002 109.209 179.818 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.482 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -139.41 146.68 40.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.56999999999999995 109.634 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.638 HG21 ' O ' ' A' ' 81' ' ' ARG . 13.5 t -38.63 110.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.426 -0.796 . . . . 0.46000000000000002 109.352 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -62.31 -54.09 45.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.255 -0.903 . . . . 1.1799999999999999 109.195 -179.892 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASP . . . . . 0.469 ' O ' ' HG2' ' A' ' 137' ' ' GLN . 1.1 m-20 -103.12 -95.3 0.31 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.369 -0.832 . . . . 1.9399999999999999 109.194 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLN . . . . . 0.469 ' HG2' ' O ' ' A' ' 136' ' ' ASP . 51.4 mt-30 -157.14 52.96 0.49 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.409 -0.807 . . . . 2.27 109.122 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 80' ' ' VAL . 25.8 mm-40 -93.71 113.64 25.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 1.51 109.729 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.67 -8.69 59.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.32000000000000001 108.768 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -138.35 134.88 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.811 -0.811 . . . . 0.34999999999999998 108.811 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.487 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -141.26 172.01 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.14 -0.975 . . . . 0.28999999999999998 110.006 -179.781 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ARG . . . . . 0.562 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.6 ptm180 -148.86 133.51 17.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.541 -0.725 . . . . 1.75 109.35 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ALA . . . . . 0.765 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.44 107.95 33.22 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.344 -0.847 . . . . 0.28000000000000003 109.613 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.3 Cg_endo -75.84 110.81 3.15 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.269 1.979 . . . . 0.34000000000000002 110.396 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ILE . . . . . 0.741 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.8 mm -91.82 129.74 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.177 -1.046 . . . . 1.1699999999999999 108.177 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' HIS . . . . . 0.661 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 9.8 m80 -89.44 156.96 18.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.913 -1.117 . . . . 0.82999999999999996 110.691 -178.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.701 ' CE1' HG13 ' A' ' 101' ' ' VAL . 61.2 m-85 -161.12 156.63 24.73 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.323 -0.991 . . . . 1.6599999999999999 108.323 179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.584 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.09 53.25 0.62 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.394 -1.483 . . . . 0.53000000000000003 109.394 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.658 ' C ' HG11 ' A' ' 64' ' ' VAL . 66.3 m-85 -127.6 155.8 43.29 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.31 -1.112 . . . . 1.3100000000000001 109.346 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.515 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.7 -29.61 70.6 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.169 -0.678 . . . . 0.31 109.169 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.35 -11.79 61.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.395 -0.816 . . . . 0.32000000000000001 109.125 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.931 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 4.3 t-20 -118.33 9.6 12.52 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.947 -1.131 . . . . 1.5800000000000001 107.947 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.566 HG23 HG13 ' A' ' 64' ' ' VAL . 2.1 t -81.79 161.34 3.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.435 0.636 . . . . 0.26000000000000001 109.963 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.482 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.94 34.91 62.29 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.787 -1.325 . . . . 0.23000000000000001 109.787 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.492 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 6.6 m-20 -160.46 143.78 13.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.132 -1.217 . . . . 0.66000000000000003 109.975 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 59' ' ' VAL . 95.4 m -89.64 125.5 35.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.465 -0.939 . . . . 0.26000000000000001 108.465 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.555 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.0 OUTLIER -103.6 118.56 50.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.938 -1.101 . . . . 0.22 110.185 -179.095 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.694 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.3 m-85 -100.59 127.83 46.85 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 107.907 -1.146 . . . . 1.21 107.907 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.663 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.39 140.02 45.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 120.919 -1.113 . . . . 0.28999999999999998 110.255 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ASP . . . . . 0.665 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.8 t0 -173.71 136.64 0.57 Allowed 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.292 -0.88 . . . . 1.1299999999999999 108.986 179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.31 -8.18 8.47 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.544 -1.312 . . . . 0.23000000000000001 110.036 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.678 HD21 ' HB3' ' A' ' 143' ' ' ALA . 0.4 OUTLIER -60.4 100.13 0.09 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.954 -1.321 . . . . 0.60999999999999999 108.747 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -133.6 145.61 50.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.29999999999999999 109.763 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.764 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 3.5 mt -125.3 108.99 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.81999999999999995 109.307 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.958 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -156.39 151.37 26.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.177 -0.952 . . . . 0.81999999999999995 109.63 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 24.9 p -87.11 171.56 10.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 1.6100000000000001 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.482 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 0.3 OUTLIER -105.94 161.09 23.91 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 3.4199999999999999 109.454 179.986 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 168' ' ' PRO . . . . . 0.482 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.2 Cg_endo . . . . . 0 C--N 1.307 -1.655 0 C-N-CA 122.733 2.289 . . . . 4.5300000000000002 110.409 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.8 ttt . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.463 -0.569 . . . . 1.79 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.7 mt -66.79 -171.39 0.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 1.89 109.468 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.958 ' CG2' ' HB2' ' A' ' 165' ' ' ALA . 3.0 p -178.19 173.94 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.61 109.484 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.764 ' HB3' ' O ' ' A' ' 164' ' ' ILE . . . -71.18 -60.71 2.09 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.53 109.403 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.637 ' HB2' HD12 ' A' ' 164' ' ' ILE . 54.0 t-20 -75.78 131.68 39.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 1.8 109.394 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.516 ' O ' ' CA ' ' A' ' 27' ' ' GLY . 4.0 mt -110.09 125.93 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.271 -0.893 . . . . 1.14 109.558 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.543 ' HB3' ' HA3' ' A' ' 27' ' ' GLY . 0.1 OUTLIER 57.75 30.1 18.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 1.75 109.679 179.874 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 162' ' ' LEU . . . -67.2 -8.98 53.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.395 -1.482 . . . . 0.71 109.395 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.498 ' HA3' ' OD1' ' A' ' 160' ' ' ASP . . . -123.02 16.33 8.2 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.499 -1.44 . . . . 1.06 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.591 ' CE1' ' HB2' ' A' ' 57' ' ' LEU . 18.7 m-85 63.66 17.3 10.33 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -1.157 . . . . 2.66 109.484 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.518 ' OE2' ' CG ' ' A' ' 52' ' ' GLU . 10.2 mt-10 -60.61 -49.83 75.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.24 -0.913 . . . . 2.11 109.528 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.523 ' CB ' ' OD1' ' A' ' 7' ' ' ASN . 0.3 OUTLIER -85.15 14.71 4.81 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 1.44 109.527 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.658 HG21 HG22 ' A' ' 25' ' ' VAL . 1.9 m -107.34 128.38 26.09 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.211 -0.931 . . . . 0.83 109.27 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 15' ' ' ALA . 35.1 Cg_endo -76.97 130.79 11.58 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.491 2.128 . . . . 0.6 110.642 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' A' ' 14' ' ' PRO . . . -43.45 169.21 0.0 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.725 -0.609 . . . . 0.43 109.624 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 130.25 132.22 3.41 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 108.992 -1.643 . . . . 0.38 108.992 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' CG ' ' A' ' 43' ' ' GLU . 0.5 OUTLIER -56.75 142.44 12.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.232 -1.158 . . . . 0.43 109.153 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 41.2 t -84.84 146.88 6.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.434 -0.791 . . . . 0.41 110.311 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 5.4 p -110.24 -25.49 10.12 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.46 -0.941 . . . . 1.33 108.46 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.545 ' HB3' ' CG ' ' A' ' 23' ' ' GLU . 2.5 m-20 -141.86 94.93 2.73 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.599 -0.889 . . . . 1.6 108.599 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.999 HD13 ' O ' ' A' ' 30' ' ' LEU . 0.5 OUTLIER -50.17 -34.36 22.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.264 -0.898 . . . . 1.26 109.909 -179.177 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.921 ' N ' HD12 ' A' ' 21' ' ' LEU . . . -64.3 -39.72 94.49 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.194 -0.941 . . . . 0.98 109.365 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.545 ' CG ' ' HB3' ' A' ' 20' ' ' ASP . 5.0 pt-20 -118.74 36.91 4.25 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.295 -0.878 . . . . 1.86 109.483 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -98.21 -76.69 1.29 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.403 -1.479 . . . . 1.18 109.403 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.658 HG22 HG21 ' A' ' 13' ' ' THR . 58.6 t -95.34 128.14 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -1.149 . . . . 1.26 109.119 179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -68.04 -36.38 79.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.284 -0.885 . . . . 1.87 109.86 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 7' ' ' ASN . . . -84.49 -13.93 72.11 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 110.071 -1.212 . . . . 0.48 110.071 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TRP . . . . . 0.619 ' CE3' ' HB1' ' A' ' 73' ' ' ALA . 1.0 OUTLIER -139.02 126.37 21.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.039 -1.271 . . . . 0.42 110.141 -179.778 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.762 ' C ' HD23 ' A' ' 30' ' ' LEU . 0.6 OUTLIER -118.86 144.09 46.58 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 108.103 -1.073 . . . . 1.44 108.103 178.826 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.999 ' O ' HD13 ' A' ' 21' ' ' LEU . 1.0 OUTLIER -118.31 161.76 19.4 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.753 -1.217 . . . . 0.62 109.739 -179.41 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -154.33 123.3 6.33 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.435 -0.791 . . . . 1.15 109.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.899 HG12 HG21 ' A' ' 36' ' ' VAL . 0.0 OUTLIER -108.82 137.68 39.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.344 -0.847 . . . . 0.4 109.674 179.739 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.61 179.59 23.56 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.403 -1.479 . . . . 0.41 109.403 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 36.3 m -58.84 -14.88 10.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.176 -1.191 . . . . 1.35 109.392 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.505 ' HB3' ' HB2' ' A' ' 67' ' ' ASN . 1.9 p -63.69 -36.57 84.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.228 -0.92 . . . . 0.91 109.597 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.899 HG21 HG12 ' A' ' 32' ' ' VAL . 2.1 t -66.32 93.11 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.158 -0.964 . . . . 0.53 109.726 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 92.8 m -74.73 -27.22 60.27 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.428 -0.795 . . . . 1.04 108.926 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.681 ' O ' HG13 ' A' ' 36' ' ' VAL . 1.2 t-20 -111.31 141.4 24.34 Favored Pre-proline 0 C--N 1.296 -1.752 0 N-CA-C 109.212 -0.662 . . . . 1.92 109.212 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.477 ' HD2' ' OD1' ' A' ' 38' ' ' ASN . 35.2 Cg_endo -76.95 111.85 3.31 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.466 2.111 . . . . 1.36 110.679 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.537 ' HG3' ' CG1' ' A' ' 71' ' ' ILE . 35.2 Cg_endo -78.02 166.91 24.3 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.573 2.182 . . . . 0.76 109.859 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.601 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 41.9 t -109.57 122.64 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.092 -1.005 . . . . 0.25 110.413 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.745 ' CD1' HD13 ' A' ' 30' ' ' LEU . 40.2 m-85 -110.96 112.81 24.91 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.107 -1.072 . . . . 1.45 108.107 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.533 ' CG ' ' HA ' ' A' ' 17' ' ' VAL . 1.8 tm-20 -151.52 145.77 25.41 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.125 -0.985 . . . . 1.61 109.932 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.95 148.57 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.368 -0.832 . . . . 0.38 109.323 179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 1.053 HD21 HG23 ' A' ' 47' ' ' THR . 0.4 OUTLIER -137.12 147.7 46.18 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.179 -0.951 . . . . 1.97 108.884 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.598 ' N ' ' HG ' ' A' ' 45' ' ' LEU . 11.7 mt-10 -112.0 111.98 23.28 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.572 -0.705 . . . . 1.86 109.478 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 1.053 HG23 HD21 ' A' ' 45' ' ' LEU . 2.0 p -135.16 144.56 47.1 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.395 -0.815 . . . . 1.18 109.486 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.9 m -68.44 -18.06 64.34 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 1.84 109.506 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 50' ' ' ALA . 4.1 m-20 -76.56 -10.74 59.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.902 . . . . 1.78 109.514 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.464 ' HB3' ' HA ' ' A' ' 54' ' ' ASN . . . -44.04 147.83 0.87 Allowed Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.256 -0.903 . . . . 0.57 109.436 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HB2' ' CG ' ' A' ' 91' ' ' TRP . 35.6 Cg_endo -78.21 -41.11 0.3 Allowed 'Trans proline' 0 C--N 1.307 -1.651 0 C-N-CA 122.771 2.314 . . . . 0.74 110.372 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' CG ' ' OE2' ' A' ' 11' ' ' GLU . 0.6 OUTLIER -126.31 108.19 11.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 2.2 109.364 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.43 ' O ' ' CG ' ' A' ' 54' ' ' ASN . . . 81.89 -121.56 5.46 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.437 -1.465 . . . . 0.61 109.437 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 46' ' ' GLU . 5.1 m120 -159.12 23.33 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -1.134 . . . . 2.26 109.513 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.523 ' CB ' ' O ' ' A' ' 10' ' ' PHE . 43.5 mttt -134.15 139.55 45.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 1.28 109.61 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.665 HG12 ' CB ' ' A' ' 160' ' ' ASP . 4.1 m -148.18 174.5 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.288 -0.883 . . . . 0.44 109.462 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LEU . . . . . 0.634 HD21 ' CG2' ' A' ' 59' ' ' VAL . 0.1 OUTLIER -104.8 99.23 8.88 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.251 -0.906 . . . . 0.25 108.983 179.544 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.671 ' CB ' ' CE2' ' A' ' 158' ' ' TYR . . . -81.71 114.09 20.14 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.288 -0.883 . . . . 0.18 108.762 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.805 ' O ' HG23 ' A' ' 156' ' ' THR . 27.5 t -110.58 144.97 17.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.217 -0.927 . . . . 0.17 109.042 -179.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . 0.555 ' CB ' ' HB ' ' A' ' 41' ' ' VAL . 3.2 m -108.04 89.13 2.9 Favored 'General case' 0 C--N 1.283 -2.29 0 N-CA-C 108.966 -0.753 . . . . 0.27 108.966 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' VAL . . . . . 0.555 HG21 ' CD1' ' A' ' 157' ' ' ILE . 39.0 t -83.43 129.39 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.32 -0.862 . . . . 0.29 109.228 -179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -160.08 61.58 0.35 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.53 109.776 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.41 ' HA3' ' HB2' ' A' ' 38' ' ' ASN . . . 150.14 94.92 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.785 -1.326 . . . . 0.3 109.785 179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.658 HG11 ' C ' ' A' ' 149' ' ' TYR . 2.3 m -79.95 -171.27 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.187 -1.184 . . . . 0.34 109.455 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 35' ' ' SER . . . -132.66 -162.97 10.46 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.588 -1.405 . . . . 0.44 109.588 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -85.14 4.12 35.88 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.267 -1.137 . . . . 1.67 109.511 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.591 ' HB3' ' CE2' ' A' ' 69' ' ' TRP . 89.7 m-20 -127.94 149.34 70.53 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 1.51 109.447 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.557 ' O ' ' CE1' ' A' ' 149' ' ' TYR . 36.2 Cg_endo -78.61 13.35 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 C-N-CA 122.643 2.229 . . . . 0.55 110.735 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.591 ' CE2' ' HB3' ' A' ' 67' ' ' ASN . 2.1 p90 -135.34 56.93 1.82 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.073 -1.017 . . . . 0.69 109.888 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.56 ' CB ' HG23 ' A' ' 36' ' ' VAL . 0.4 OUTLIER -79.29 -67.53 0.75 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -0.91 . . . . 1.41 109.077 179.607 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.73 HG23 ' HZ ' ' A' ' 42' ' ' PHE . 3.2 mp -98.52 128.67 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.328 -0.858 . . . . 0.62 108.926 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 145' ' ' ILE . 43.0 tt0 -134.46 122.05 21.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.069 -1.019 . . . . 2.07 109.893 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . 0.741 ' O ' HG12 ' A' ' 145' ' ' ILE . . . -114.69 108.31 16.63 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.285 -0.884 . . . . 0.39 108.785 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.518 HG22 ' N ' ' A' ' 75' ' ' ALA . 91.4 m -97.94 163.08 12.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.433 -0.792 . . . . 0.39 109.782 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.518 ' N ' HG22 ' A' ' 74' ' ' THR . . . -118.32 139.67 50.99 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.109 -0.994 . . . . 0.34 109.099 179.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.699 ' HB2' ' HA ' ' A' ' 77' ' ' PRO . 2.2 p90 175.84 169.32 0.37 Allowed Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.503 -0.748 . . . . 1.44 109.066 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.699 ' HA ' ' HB2' ' A' ' 76' ' ' PHE . 36.6 Cg_endo -80.51 165.07 78.09 Favored 'Cis proline' 0 C--N 1.309 -1.529 0 C-N-CA 123.549 -1.438 . . . . 0.47 110.654 -0.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.707 HG11 HD13 ' A' ' 164' ' ' ILE . 90.0 t -124.61 156.18 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.333 -0.855 . . . . 0.36 108.995 179.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASN . . . . . 0.46 ' O ' ' CB ' ' A' ' 4' ' ' ALA . 76.2 m-20 -123.35 122.48 38.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 1.34 109.917 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.58 ' HA ' ' CZ ' ' A' ' 86' ' ' TYR . 2.7 m -126.89 -173.96 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.901 . . . . 0.33 109.44 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.638 ' O ' HG21 ' A' ' 134' ' ' VAL . 3.5 mtt180 -136.09 146.61 57.23 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.297 -0.877 . . . . 2.85 109.293 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -76.78 103.73 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.589 2.193 . . . . 0.47 110.467 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 115.91 -35.78 4.13 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.601 -1.4 . . . . 0.45 109.601 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 t -82.3 149.49 4.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.267 -1.137 . . . . 0.53 109.667 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 132' ' ' PHE . 24.1 m -97.19 134.95 39.83 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 109.37 -0.604 . . . . 1.21 109.37 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . 0.58 ' CZ ' ' HA ' ' A' ' 80' ' ' VAL . 6.2 m-85 -108.84 171.58 7.35 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 1.25 109.603 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 164' ' ' ILE . 4.2 m -118.18 154.22 32.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.296 -0.878 . . . . 0.56 109.477 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.693 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 5.3 t80 -130.97 117.39 19.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.295 -0.878 . . . . 4.95 109.324 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.506 ' O ' ' O ' ' A' ' 161' ' ' GLY . 18.6 m -135.19 143.59 46.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.933 . . . . 0.28 109.337 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.725 HD13 ' CD2' ' A' ' 103' ' ' PHE . 17.4 tt -150.17 163.07 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.865 -1.147 . . . . 0.41 109.473 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.604 ' CG ' ' HB2' ' A' ' 51' ' ' PRO . 20.5 m95 -131.68 126.58 34.93 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.989 -1.069 . . . . 0.3 109.235 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 125' ' ' TRP . . . -114.79 148.26 38.66 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.268 -0.895 . . . . 0.3 109.568 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.563 ' HD3' ' CE2' ' A' ' 125' ' ' TRP . 19.2 ttp85 -162.64 121.49 2.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 1.85 109.222 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 123' ' ' THR . . . -109.13 152.44 25.09 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.907 . . . . 0.21 109.825 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.413 ' HB2' ' HB ' ' A' ' 156' ' ' THR . 0.2 OUTLIER -52.09 -36.96 52.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.356 -0.84 . . . . 2.05 109.408 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.542 ' C ' HG22 ' A' ' 123' ' ' THR . 2.9 mt-30 -121.05 143.0 49.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.263 -0.898 . . . . 2.23 109.41 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.634 ' N ' HG22 ' A' ' 123' ' ' THR . 30.4 p30 -68.89 164.25 22.53 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.246 -0.909 . . . . 1.92 109.494 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 88.48 43.9 5.4 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.611 -1.395 . . . . 0.34 109.611 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.931 ' HB1' ' OD1' ' A' ' 152' ' ' ASN . . . -122.96 142.54 50.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.192 -1.181 . . . . 0.26 108.917 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 46.3 t -114.5 145.83 19.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 O-C-N 121.178 -0.952 . . . . 0.28 110.725 -179.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.701 HG13 ' CE1' ' A' ' 147' ' ' PHE . 60.5 t -146.93 163.59 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.545 -0.722 . . . . 0.31 109.368 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.661 ' HB2' ' HB2' ' A' ' 146' ' ' HIS . 49.4 m -127.29 132.45 50.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.106 -0.997 . . . . 1.33 109.702 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.725 ' CD2' HD13 ' A' ' 90' ' ' ILE . 0.3 OUTLIER -128.28 104.27 7.64 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.173 -0.954 . . . . 1.39 109.636 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.584 ' O ' ' HD2' ' A' ' 144' ' ' PRO . 18.2 p -122.72 168.9 11.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.132 -0.98 . . . . 0.36 110.512 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' A' ' 143' ' ' ALA . 0.1 OUTLIER -125.58 152.92 32.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 CA-C-O 121.271 0.558 . . . . 0.46 109.762 -179.822 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 111' ' ' GLN . . . 179.19 148.26 7.64 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.529 -1.428 . . . . 0.62 109.529 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.473 ' HB3' HG22 ' A' ' 141' ' ' ILE . 0.0 OUTLIER -92.21 -170.65 2.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.177 -1.19 . . . . 2.14 109.635 -179.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -61.43 -26.5 67.91 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.27 -0.894 . . . . 1.13 110.64 -179.068 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.49 ' HB3' ' HG2' ' A' ' 111' ' ' GLN . 0.3 OUTLIER -79.42 9.31 4.92 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.072 -1.017 . . . . 1.55 110.04 -179.475 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PHE . . . . . 0.52 ' N ' ' CD1' ' A' ' 110' ' ' PHE . 3.6 m-30 71.75 1.89 4.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.256 -0.903 . . . . 1.68 109.809 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLN . . . . . 0.49 ' HG2' ' HB3' ' A' ' 109' ' ' SER . 12.0 mm100 -69.89 104.51 2.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.161 -0.962 . . . . 2.24 109.135 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 105' ' ' VAL . 6.3 tt0 -89.28 144.52 26.03 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.299 -0.875 . . . . 1.62 109.825 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.576 ' O ' ' CZ ' ' A' ' 132' ' ' PHE . 6.1 m-85 -107.97 -69.87 0.83 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.419 -0.801 . . . . 1.5 109.005 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.546 ' HA2' ' CE2' ' A' ' 132' ' ' PHE . . . -86.42 162.8 35.13 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.232 -1.547 . . . . 0.5 109.232 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.533 ' CG ' ' O ' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -157.59 116.16 3.19 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.07 -1.253 . . . . 2.97 110.103 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 130' ' ' PHE . 0.0 OUTLIER -147.46 81.39 1.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.56 108.893 179.391 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.556 ' HB2' ' CB ' ' A' ' 102' ' ' SER . 34.5 p-80 -126.38 166.07 17.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 3.64 110.083 -179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 117' ' ' HIS . 6.9 tt0 77.36 57.12 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.38 -0.825 . . . . 2.51 109.351 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 mt-30 -137.81 144.06 41.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.303 -0.873 . . . . 2.29 109.731 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLN . . . . . 0.633 ' O ' HD13 ' A' ' 121' ' ' ILE . 38.6 mt-30 -75.6 156.77 34.6 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.516 -0.74 . . . . 2.03 109.062 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.633 HD13 ' O ' ' A' ' 120' ' ' GLN . 13.3 mm -132.91 138.44 51.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.189 -0.945 . . . . 0.38 110.012 -179.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -81.21 -179.34 7.32 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.516 -0.74 . . . . 0.27 110.061 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.634 HG22 ' N ' ' A' ' 97' ' ' ASP . 81.9 p -78.64 2.64 18.74 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.931 -0.708 . . . . 0.4 109.283 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.501 ' CA ' ' HG3' ' A' ' 93' ' ' ARG . 35.9 mt-10 -112.6 -169.06 1.4 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.224 -0.922 . . . . 2.01 109.375 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' TRP . . . . . 0.58 ' CE3' ' HG3' ' A' ' 51' ' ' PRO . 88.8 m95 -93.6 126.96 39.05 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.245 -0.909 . . . . 0.44 109.575 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 91' ' ' TRP . 2.3 mt-30 -106.97 121.21 45.57 Favored Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.192 -0.942 . . . . 1.65 109.033 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.586 ' HB3' ' CZ2' ' A' ' 91' ' ' TRP . 36.4 Cg_endo -79.33 103.72 1.66 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.515 2.143 . . . . 0.32 110.864 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.45 134.68 54.82 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.276 -1.009 . . . . 1.28 108.276 179.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' ' 88' ' ' TYR . 15.2 t -151.65 176.96 10.85 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 122.485 1.136 . . . . 0.4 110.866 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.693 ' CE2' ' CG ' ' A' ' 88' ' ' TYR . 34.4 p90 -170.43 -174.71 1.73 Allowed 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.064 -0.971 . . . . 1.47 109.281 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 45.5 mt-10 -129.81 150.24 51.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.178 -0.951 . . . . 1.5 109.869 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.576 ' CZ ' ' O ' ' A' ' 113' ' ' TYR . 0.7 OUTLIER -164.91 168.14 17.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.849 . . . . 4.28 109.209 179.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.482 ' O ' ' C ' ' A' ' 134' ' ' VAL . 0.5 OUTLIER -139.41 146.68 40.45 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.57 109.634 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.638 HG21 ' O ' ' A' ' 81' ' ' ARG . 13.5 t -38.63 110.39 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.426 -0.796 . . . . 0.46 109.352 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.407 ' HB2' ' CE1' ' A' ' 113' ' ' TYR . 0.3 OUTLIER -62.31 -54.09 45.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.255 -0.903 . . . . 1.18 109.195 -179.892 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.469 ' O ' ' HG2' ' A' ' 137' ' ' GLN . 1.1 m-20 -103.12 -95.3 0.31 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.369 -0.832 . . . . 1.94 109.194 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.469 ' HG2' ' O ' ' A' ' 136' ' ' ASP . 51.4 mt-30 -157.14 52.96 0.49 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.409 -0.807 . . . . 2.27 109.122 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 80' ' ' VAL . 25.8 mm-40 -93.71 113.64 25.76 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.243 -0.911 . . . . 1.51 109.729 -179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 2.6 p -79.67 -8.69 59.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.239 -0.913 . . . . 0.32 108.768 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 38.6 t -138.35 134.88 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.811 -0.811 . . . . 0.35 108.811 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.487 ' O ' ' HB ' ' A' ' 78' ' ' VAL . 0.7 OUTLIER -141.26 172.01 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.14 -0.975 . . . . 0.29 110.006 -179.781 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ARG . . . . . 0.562 ' O ' ' HD3' ' A' ' 144' ' ' PRO . 1.6 ptm180 -148.86 133.51 17.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.541 -0.725 . . . . 1.75 109.35 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ALA . . . . . 0.765 ' HA ' ' HA ' ' A' ' 105' ' ' VAL . . . -94.44 107.95 33.22 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.344 -0.847 . . . . 0.28 109.613 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PRO . . . . . 0.584 ' HD2' ' O ' ' A' ' 104' ' ' THR . 34.3 Cg_endo -75.84 110.81 3.15 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.269 1.979 . . . . 0.34 110.396 179.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ILE . . . . . 0.741 HG12 ' O ' ' A' ' 73' ' ' ALA . 2.8 mm -91.82 129.74 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.177 -1.046 . . . . 1.17 108.177 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' HIS . . . . . 0.661 ' HB2' ' HB2' ' A' ' 102' ' ' SER . 9.8 m80 -89.44 156.96 18.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.913 -1.117 . . . . 0.83 110.691 -178.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.701 ' CE1' HG13 ' A' ' 101' ' ' VAL . 61.2 m-85 -161.12 156.63 24.73 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.323 -0.991 . . . . 1.66 108.323 179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.584 ' C ' HG12 ' A' ' 64' ' ' VAL . . . 109.09 53.25 0.62 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.394 -1.483 . . . . 0.53 109.394 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.658 ' C ' HG11 ' A' ' 64' ' ' VAL . 66.3 m-85 -127.6 155.8 43.29 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.31 -1.112 . . . . 1.31 109.346 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.515 ' N ' HG11 ' A' ' 64' ' ' VAL . . . -64.7 -29.61 70.6 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.169 -0.678 . . . . 0.31 109.169 -179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 99' ' ' ALA . . . -71.35 -11.79 61.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.395 -0.816 . . . . 0.32 109.125 179.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.931 ' OD1' ' HB1' ' A' ' 99' ' ' ALA . 4.3 t-20 -118.33 9.6 12.52 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.947 -1.131 . . . . 1.58 107.947 179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.566 HG23 HG13 ' A' ' 64' ' ' VAL . 2.1 t -81.79 161.34 3.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 121.435 0.636 . . . . 0.26 109.963 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.482 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . 55.94 34.91 62.29 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.787 -1.325 . . . . 0.23 109.787 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.492 ' OD1' ' HB2' ' A' ' 96' ' ' GLN . 6.6 m-20 -160.46 143.78 13.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.132 -1.217 . . . . 0.66 109.975 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 59' ' ' VAL . 95.4 m -89.64 125.5 35.27 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.465 -0.939 . . . . 0.26 108.465 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.555 ' CD1' HG21 ' A' ' 61' ' ' VAL . 1.0 OUTLIER -103.6 118.56 50.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.938 -1.101 . . . . 0.22 110.185 -179.095 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.694 ' CE1' HG22 ' A' ' 156' ' ' THR . 2.3 m-85 -100.59 127.83 46.85 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 107.907 -1.146 . . . . 1.21 107.907 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.663 HD13 ' CZ ' ' A' ' 147' ' ' PHE . 1.2 mt -120.39 140.02 45.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 120.919 -1.113 . . . . 0.29 110.255 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ASP . . . . . 0.665 ' CB ' HG12 ' A' ' 56' ' ' VAL . 9.8 t0 -173.71 136.64 0.57 Allowed 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.292 -0.88 . . . . 1.13 108.986 179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 160' ' ' ASP . . . 124.31 -8.18 8.47 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.544 -1.312 . . . . 0.23 110.036 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.678 HD21 ' HB3' ' A' ' 143' ' ' ALA . 0.4 OUTLIER -60.4 100.13 0.09 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.954 -1.321 . . . . 0.61 108.747 179.975 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 5' ' ' ASN . . . -133.6 145.61 50.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.444 -0.785 . . . . 0.3 109.763 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.764 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 3.5 mt -125.3 108.99 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.82 109.307 179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.958 ' HB2' ' CG2' ' A' ' 3' ' ' VAL . . . -156.39 151.37 26.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.177 -0.952 . . . . 0.82 109.63 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' SER . . . . . . . . . . . . . 24.9 p -87.11 171.56 10.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.341 -0.849 . . . . 1.61 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.482 ' HB2' ' HD2' ' A' ' 168' ' ' PRO . 0.3 OUTLIER -105.94 161.09 23.91 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.29 -0.881 . . . . 3.42 109.454 179.986 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' PRO . . . . . 0.482 ' HD2' ' HB2' ' A' ' 167' ' ' GLN . 35.2 Cg_endo . . . . . 0 C--N 1.307 -1.655 0 C-N-CA 122.733 2.289 . . . . 4.53 110.409 -179.988 . . . . . . . . 1 1 . 1 stop_ save_